A combination of methotrexate and irradiation promotes cell death in NK/T-cell lymphoma cells via down-regulation of NF-κB signaling

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 350-357

  Kim, Areumnuri ^a,b   Lee, Jung Eun ^a   Jang, Won Suk ^a   Lee, Sun Joo ^a   Park, Sunhoo ^a,b   Kang, Hye Jin ^a   Lee, Seung Sook ^a,b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

Extranodal NK T cell; Lymphoma; Methotrexate; NF kappa b; Radiotherapy

Indexed keywords

BETA ACTIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; METHOTREXATE; NUCLEAR FACTOR KAPPA B P50 SUBUNIT; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRRADIATION; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CESIUM RADIOISOTOPES; CHEMORADIOTHERAPY; CYTOPLASM; DOWN-REGULATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GAMMA RAYS; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; METHOTREXATE; NF-KAPPA B; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84855953596     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.027     Document Type: Article

References (39)

1. Chan J.K.C., Quintanilla-Martinez L., Ferry J.A., et al. Extranodal NK/T-cell lymphoma, nasal type. WHO classification of tumours of hematopoietic and lymphoid tissues 2008, 285-288. IRAC Press, Lyon. S.H. Swerdlow (Ed.).
2. Bahl G., Laskar S., Muckaden M.A. Radiotherapy alone for nasal natural-killer/T-cell lymphoma. J Clin Oncol 2006, 24:2684-2685. [author reply 2685-6].
3. Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006, 24:181-189.
4. Li C.C., Tien H.F., Tang J.L., et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004, 100:366-375.
5. Au W.Y., Weisenburger D.D., Intragumtornchai T., et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009, 113:3931-3937.
6. Cheung M.M., Chan J.K., Lau W.H., Ngan R.K., Foo W.W. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002, 54:182-190.
7. Vose J., Armitage J., Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
8. Yamaguchi M., Kita K., Miwa H., et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995, 76:2351-2356.
9. Wang B., Li X.Q., Ma X., Hong X., Lu H., Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 2008, 83:795-799.
10. Kim S.J., Kim K., Kim B.S., et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009, 27:6027-6032.
11. Yamaguchi M., Tobinai K., Oguchi M., et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009, 27:5594-5600.
12. Kim B.S., Kim D.W., Im S.A., et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 2009, 20:121-128.
13. Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
14. Kanavaros P., Lescs M.C., Briere J., et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993, 81:2688-2695.
15. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
16. Zhang Y., Ohyashiki J.H., Takaku T., Shimizu N., Ohyashiki K. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection. Br J Cancer 2006, 94:599-608.
17. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
18. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
19. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
20. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
21. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923-5929.
22. Bernal-Mizrachi L., Lovly C.M., Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006, 103:9220-9225.
23. Kim K., Ryu K., Ko Y., Park C. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005, 131:59-66.
24. Criswell T., Leskov K., Miyamoto S., Luo G., Boothman D.A. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22:5813-5827.
25. Bottero V., Busuttil V., Loubat A., et al. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001, 61:7785-7791.
26. Majumdar S., Aggarwal B.B. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001, 167:2911-2920.
27. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
28. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
29. Mori N., Fujii M., Ikeda S., et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999, 93:2360-2368.
30. Demetriades C., Mosialos G. The LMP1 promoter can be transactivated directly by NF-kappaB. J Virol 2009, 83:5269-5277.
31. Kimura N., Miyakawa Y., Kohmura K., Umezawa K., Ikeda Y., Kizaki M., Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. Leuk Res 2007, 31:1529-1535.
32. Hussain A.R., Ahmed M., Al-Jomah N.A., et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008, 7:3318-3329.
33. Wong J.H., Lui V.W., Umezawa K., et al. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett 2010, 287:23-32.
34. Huang Y., de Reynies A., de Leval L., et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010, 115:1226-1237.
35. Ng S.B., Selvarajan V., Huang G., et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2010.
36. Koom W.S., Chung E.J., Yang W.I., et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004, 59:1127-1137.
37. Bentires-Alj M., Barbu V., Fillet M., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
38. Jaccard A., Gachard N., Marin B., et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
39. Brengauz-Breitmann M., Friedman E., Savion S., Torchinsky A., Fein A., Toder V. Involvement of NF-kappaB in the response of embryonic cells to methotrexate. Reprod Toxicol 2006, 22:469-478.